A Phase 2, Open Label Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K Dual δ/γ Inhibitor, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Latest Information Update: 16 Aug 2024
At a glance
- Drugs Tenalisib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Rhizen Pharmaceuticals
- 02 Nov 2020 Status changed from recruiting to completed.
- 19 Dec 2019 New trial record